Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration ...

The Carbamazepine extended-release tablets are indicated for use as an anti-convulsant drug and also for the treatment of the ...

London: GSK plc has announced the extension of the US Food and Drug Administration (FDA) review period for the Biologics ...

Lupin receives USFDA approval for generic Liraglutide Injection and Glucagon, expanding access to diabetes treatments.

Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets.

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to ...

Zydus Lifesciences receives tentative USFDA approval for its generic Ibrutinib tablets, used to treat various blood cancers.

Ibrutinib tablets had annual sales of $2,148.9 million in the United States, as per the IQVIA data dated May 2025, Zydus Life ...

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

Dr Reddy’s received a Form 483 with seven USFDA observations after inspecting its Srikakulam manufacturing plant in Andhra ...

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog, expanding their insulin ...